Volume - 12- Issue No. - 3 March 2026

Microbioz India

www.microbiozindia.com

THE BUSINESS OF SCIENCE

SCALING **PHARMA INNOVATION** IN A COMPETITIVE WORLD

Inside

RNI:UPENG/2017/73675

Price:100/-

NEW

Monodisperse Fully Porous Particles (MFPP) for HPLC

EVOSPHERE HPLC Columns

60% Increased efficiency over traditional porous particles.

Increased loadability and preparative scaling versus Core-Shell columns.

Multiple unique surface chemistries to further aid compound separation.

Significant cost savings when compared against Core-Shell columns.







EXCLUSIVELY BROUGHT TO YOU BY:

APEX CHROMATOGRAPHY

HYDERABAD OFFICE
Plot No. 35, Street No. 3
Sagar Society, Banjara Hills
Hyderabad - 500034. Telangana
Phone: +91-40-23559697 / 98
+91-98481 77772
E-mail: sales@apexchrom.com

MUMBAI OFFICE
102, A-Wing, Mangalya Building
Off Marol Maroshi Road, Andheri East,
Mumbai - 400059. Maharashtra, India
Phone: +91-22-29209697 / 98
+91-96191 77772
E-mail: sales.mumbai@apexchrom.com

www.apexchromatography.com

Hyderabad / Mumbai / Delhi / Ahmedabad / Pune / Bengaluru / Vizag / Goa / Aurangabad

A Company of:

Surface Measurement Systems
World Leader in Sorption Science



Focused on particle characterisation

World leading materials experts

PCL
Particle Characterisation Lab

Scientific Excellence
Quality Solutions
Delivered ✓

Testing, consulting, R&D, training

www.particlelaboratories.com

EXCLUSIVE NEW YEAR OFFER:

Readers of Microbioz can claim **50% off** on first pharmaceutical material analysis.

Contact us at **info@particlelaboratories.com** with this code:

MicroB-SPR26

Offer expires 30/04/2026



State-of-the-art instrumentation

Ami Polymer

Great Place To Work. Certified APR 2025-APR 2026 INDIA

Next-Generation Mixing Systems for Biopharma Manufacturing

Innovative single-use solutions enabling sterile, efficient, and scalable upstream and downstream bioprocessing.

Mixing systems are essential in modern biopharmaceutical manufacturing, ensuring sterility, product consistency, and efficient processing. With the rise of single-use technologies, mixer bag systems offer a flexible solution for upstream and downstream applications. Manufactured in ISO Class 7/8 cleanrooms, they reduce contamination risks, simplify validation, and enhance operational efficiency.

APPLICATIONS IN BIOPHARMA

UPSTREAM PROCESSING	DOWNSTREAM PROCESSING
- Media Preparation - Buffer Preparation - Cell Culture Applications - Process & Fluid Transfer	- Buffer & Reagent Preparation - Process Intermediates - Virus Inactivation - Final Formulation & Fill-Finish

KEY FEATURES

- Custom-designed configurations for specific bioprocess requirements
- Precision-engineered impeller for uniform and consistent mixing
- High burst strength ensuring operational safety and durability
- Protects sensitive biological molecules during mixing
- 100% integrity tested with pressure leak validation
- Easy inlet and outlet connectivity
- Available in scalable volumes: **50L | 100L | 200L | 500L | 1000L**

THE ROLE OF ADVANCED POLYMER SOLUTIONS

High-performance polymer components such as silicone tubing, single-use assemblies, gaskets, and molded parts ensure sterility, durability, and chemical compatibility.

Ami Polymer provides advanced polymer solutions that support safe, scalable, and compliant mixing technologies for the biopharmaceutical industry.

www.amipolymer.com

media@amipolymer.com

One Step
RT-qPCR Master Mix (2×)

Sensitivity & Simplicity — In One Tube

One Step RT-qPCR Master Mix (2×) accelerates your RNA research by integrating high-efficiency reverse transcription and real-time PCR amplification into a streamlined, single-tube protocol. By eliminating intermediate steps required in conventional two-step methods, it significantly reduces the risk of cross-contamination while saving valuable laboratory time.

Why Choose It?

- ✓ **True One-Step Workflow** – Reverse Transcription + qPCR in a single reaction
- ✓ **High Sensitivity & Specificity** – Reliable detection of low copy RNA targets
- ✓ **Hot Start Taq Technology** – Reduced background, enhanced accuracy
- ✓ **Thermostable Reverse Transcriptase** – Efficient cDNA synthesis
- ✓ **Optimized Buffer System** – Consistent and reproducible performance
- ✓ **Compatible with ROX & Probe-based assays** (appropriate TaqMan probe needs to be added separately based on the specific assay requirements)

Designed for:

- Gene Expression Studies
- Viral Detection
- Probe Based DNA Quantification
- Research Applications

Faster Setup
Fewer Errors
Superior Results

Available Pack Size 500mcl (50 reaction)
For Research Use Only

endless process of science...

Connect with us: SRL Sisco Research Laboratories
marketing@srlchem.com +91 22-42685800

Certifications: DNV ISO 9001 · ecovadis · GMP · Star Export House · CE · D-U-N-S Registered · FDA Food and Drug Administration

We're pleased to inform you that we're
A Leading Supplier of the following
Spectroscopy & Chromatography Consumables:

Hiten Techno Products Corporation

1. D2 Lamps
(i) Hamamatsu Photonics K.K., Japan
(ii) Mitorika Co., Ltd., Japan
(iii) Excelitas Noblelight GmbH, Germany

2. HPLC Vials, Caps & Septa
(Cole-Parmer Instrument Company LLC, USA)

3. Spectroscopy Cuvettes
(Starna Scientific Ltd., UK)

4. Certified Reference Materials for Calibrating Spectrophotometers & Spectrofluorometers
(Starna Scientific Ltd., UK)

5. Polystyrene Films for Calibrating FTIRs
(Starna Scientific Ltd., UK)

6. FTIR Cells, Windows & Accessories
(Specac Ltd., UK)

7. Hollow Cathode Lamps
(Mitorika Co., Ltd., Japan)

8. NMR & EPR Sample Tubes
(Norell Inc., USA)

9. Weighing Balances
(Adam Equipment Co. Ltd., UK)

10. Short-Arc Xenon lamps (Ushio Inc., Japan)

11. 96-Well Quartz Microplate
(Starna Scientific Ltd., UK)

912, The Capital, Adjoining Jio Garden, G Block, Bandra Kurla Complex, Mumbai - 400 051, India.Tel: +91-22-66268000 (100 lines)
Email: hemang.jhaveri@hitentechno.com | www.hitentechno.in

GLASSCO®

BEGINS WITH CLARITY

Automatic Solvent Extraction System

DAN.FAS.01

Sample Size	0.1 To 8g (depending on Sample Type)
Energy Mode	PID With Auto Tuning Facility
Heat Temp. Control	35°C(Ambient) To 250°c
Power Consumption	2200W
Voltage	240V/50Hz
Dimensions	875 x 420 x 680 mm

Automatic Fibre Extraction System

DAN.CFES.01

SAMPLE SIZE	0.1 to 4g (depending on sample type)
TEMP. RANGE CONTROL	RT to 450°C
Temperature Accuracy	±0.5°C
MEASURING RANGE	0.1 % - 100 %
Heat Source	Ceramic Infrared Heater
Crucibles	Sintered silica glass crucibles with P1 porosity disc (6Nos.)
Extractor	Marked borosilicate extraction vessel
Temperature Control	PID with auto-tuning facility
Power Consumption	2800W
VOLTAGE	240V/50Hz
DIMENSIONS	710 x 515 x 680 mm

Visit us at:

analytica Lab India

22 23 24 APRIL 2026

Stand No. J027

MUMBAI, INDIA

ChemExpo® INDIA

Presented by: ChemicalWeekly

29 30 APRIL 2026

Hall 3 | Stand No. 3B23

MUMBAI, INDIA

Glassco Laboratory Equipments Pvt. Ltd.

Mob.:+91 91 69 014 014 | Email: enquiry@glasscolabs.com | Website: glasscolabs.com

eppendorf

Accelerate Your Growth

Discover the new, large-capacity CellXpert® CS220 CO_2 Incubator Shaker

Do you want to accelerate your research while minimizing the risk of costly delays for your mammalian suspension cultures? Discover the only CO_2 incubator shaker in the market with an integrated 180 °C sterilization and an outstanding capacity-to-footprint ratio. Learn more about the cost- and time-saving features that will help your team remain focused on the tasks critical to your success.

- > Integrated 180 °C chamber sterilization routine
- > Up to 40 % higher flask capacity and highest platform size to footprint ratio
- > Seamless stainless-steel chamber with few internal parts
- > Powerful evaporation protection with active bidirectional, non-condensing humidity control

eppendorf.group/accelerate_your_growth

TABLE OF CONTENTS

High performance **DEGASi®** Flat Film in-line degasser and vacuum controller

srico
INNOVATIVE LABORATORY TECHNOLOGY

WIGGENS
THE MAGIC MOTION

Orbital Shaker

- Motion Type: Orbital
- Speed Range (rpm): 10 to 300
- Accuracy (rpm): ±2 (100 rpm)
- Timer: 1min to 99 hrs 59 min
- Shaking Throw:
  - 8/14/20 Available - Standard 20

Visit us at
analytica Lab India
Booth: E015
22-24 Apr, 2026
Jio World Convention Centre
Mumbai

Rocking Shaker

- Motion Type: Rocking (see-saw motion)
- ·Speed Range: 10 – 80 rpm
- ·Tilt Angle: ±7° to ±12°
- ·Timer: 1 min – 99 hr 59 min
- ·Load Capacity: 5 – 10 kg

Scientific Research Instruments Company Private Limited
#42-43, 2nd & 3rd Floor, 1st Cross, Gubbalala, Bengaluru - 560061
www.srico-labworld.com | +91 9900674407 | info@srico-labworld.com
Bengaluru | Mumbai | Hyderabad | Bhubaneswar | Vadodara | Delhi
Chennai | Goa | Thiruvananthapuram | Pune | Visakhapatnam | Kolkata | Guwahati | Ahmedabad | Chandigarh | Lucknow

New
Visit our Website

Our Staff.

Corporate Office:
Microbioz India
H1/204, Vikramaditya Tower, Alaknanda Market | Kalka Ji,
New Delhi - 110019, India
Mob:- +91-9670704431 | Tel:- +91-11-44459687
Email ID : support@microbiozindia.com

Registered with Registrar of News Paper for India with RNI No: UPENG/2017/73675

Owned, Printed, Published and Edited by Jitendra Kumar Shukla, printed at Ganapathi Overseas 1/63 Bahar-e -Sahara State Janki Puram Lucknow-226021, and Published from 631/63, Surendra Nagar, Mulayam Nagar, Chinhat - Lucknow-226016, Editor, Jitendra Kumar Shukla

Editor's Word

Dear Readers,

Welcome to a fresh and forward-looking edition of Microbioz India.

In an era where science and innovation are evolving at an unprecedented pace, our mission remains clear—to bring you content that not only informs but also inspires new perspectives and possibilities. This issue has been thoughtfully curated to reflect the dynamic landscape of the pharma, biopharma, laboratory, and analytical industries, offering you a blend of insights, innovation, and industry intelligence.

Our cover story, "**The Business of Science: Scaling Pharma Innovation in a Competitive World,**" takes you into the heart of how scientific breakthroughs are being transformed into scalable, impactful solutions. It explores the strategies, challenges, and vision that define success in today's highly competitive environment.

Adding further depth to this edition, we feature "**Mixing Systems in Biopharma Applications: Innovative Single-Use Solutions for Upstream and Downstream Processing,**" contributed by Ami Polymer—an article that highlights technological advancements shaping efficiency and precision in modern bioprocessing.

As we continue to embrace the digital evolution, Microbioz India is expanding beyond print—bringing you closer to real-time updates, multimedia experiences, and interactive engagement through our online platforms. We encourage you to explore more on our website and stay connected with us across our digital channels.

Your feedback remains at the core of our growth. It is your trust and engagement that drive us to continuously raise the bar and deliver meaningful, high-quality content tailored to your interests.

Thank you for being a valued part of the Microbioz India community. We hope this edition sparks ideas, fuels innovation, and keeps you informed on the trends shaping our industry.

Enjoy the read!

Warm regards,
Kumar

Kumar Jeetendra

Microbioz India.

Magazine Publishing Company

Cancer research:

PROGRESS AND CHALLENGES

Oncology is at the forefront of the precision medicine revolution, helping to deliver impressive gains in patient survival.

The list of actionable cancer drivers is growing at a remarkable pace, emphasizing huge progress against major drug targets such as EGFR, ALK, BCR-ABL, and more recently K-RAS. Although, even for successful cancer drugs - resistance is common and much remains to be done.

TRC is the perfect partner to help you develop the more selective, lower-toxicity drugs that are required to truly expedite therapeutic success. Our cancer research chemicals portfolio contains more than 11,000 products, with an extensive ready-to-ship catalogue including:

- APIs
- Drug derivatives
- Bioactive molecules
- Stable isotope labelled compounds

All products are delivered with a complete analytical data package as per request, including:

- **Full spectroscopic analysis - including NMR, HPLC, MS and elemental analysis**
- **COAs - purity and testing information**
- **Additional analyses on demand - such as KF and TGA**

Our large and novel range of highly characterised research chemicals can support you from early-stage research to drug discovery and toxicology.

View our cancer research catalogue

Need to discuss a specific project? We specialise in multi-step and complex custom synthesis.

Talk to our experts today!

SCAN ME

Contact us

T | +1 (416) 665-9696 I US & Canada: +1 (800) 727-9240

E | info.trc@lgcgroup.com

W I www.lgcstandards.com/TRC

THE BUSINESS OF SCIENCE

SCALING **PHARMA INNOVATION** IN A COMPETITIVE WORLD

Considering the rapid evolution of our global healthcare system, the pharmaceutical sector, as a reliable source of innovative science, also serves as a resource for innovative business practices. The modern pharmaceutical sector is no longer about just discovering and innovating. It focuses on translating scientific advancements into solutions that are commercially viable. Scaling new innovations to meet the demands of a competitive and globally regulated market is critical to the modern pharmaceutical industry.

Beyond Discovery: The Delivery of Commercially Viable Medicines: An innovative scientific discovery, such as a new chemical entity, is the beginning of a lengthy and rigorous process that can transform a new discovery into a new medicine.

The journey towards commercial viability involves various phases, including, but not limited to, the costs and complexities of clinical trials, regulatory approvals, the scale-up of manufacturing, and the global commercial distribution of the new medicine. The pharmaceutical sector strives to fulfill its obligation to meet parameters of safety, efficacy and regulatory compliance while also embracing the virtue of speed. The changing demands of the global healthcare system continue to increase the costs of drug development. The development of new and successful medicines can take in excess of several billion dollars. The changing demands of the global healthcare system will continue to impact the various business models employed within the pharmaceutical sector, with a greater focus on operational efficiencies, collaborative partnerships, and shared risk strategies.

Value in Strategic Collaborations

Collaboration is the foundation for scalable innovation in the pharmaceutical industry, as they now more than ever combine efforts with biotech companies, universities, contract research organizations, and contract development . Strategic collaborations provide opportunities to leverage additional capabilities by accessing more expertise, shortening time to market, and decreasing operational costs.

The acceleration of innovation, with the added benefit of risk diversification for drug development, is driving more of the pharmaceutical industry to adopt open innovation strategies, where organizations combine their in-house research & development and the use of external research & development.

Advancing Through Digital Technologies

Pharma is transforming its processes across the industry using AI, machine learning, and big data. Digital processes will facilitate better outcomes for patients, streamline clinical trials, and ameliorate the drug discovery process.

Additionally, the use of predictive analytics determine potential drug candidates and the understanding of patient behaviors and the effectiveness of treatments strengthen the case for the use of real-world data.

The incorporation of digital frameworks into the management of supply chains enables increased supply chain visibility and the ability to quickly adapt to changing market conditions. The pharmaceutical industry is characterized by innovation in all areas, and, therefore, the incorporation of digital technologies is imperative.

Regulatory flexibility and access to markets

An essential element in scaling novel processes in the pharmaceutical industry is management of the regulatory environment. Global regulators are becoming more flexible and initiating faster approvals and are more flexible in providing opportunities for innovation in the treatment of niche and emerging areas, including, but not limited to, rare diseases and personalized medicine.

On the other hand, gaining regulatory approval is necessary, but not sufficient to gain access to the market.

Companies will need to show not only the clinical effectiveness but also the economic impact of their new medicines due to market access, pricing, and reimbursement obstacles. How new medicines are assessed and subsequently adopted in a number of markets is being transformed by health technology assessments (HTAs) and new models of value-based pricing.

The Evolution of Customized Medicine

The customized or precision medicine approach is markedly changing the pharmaceutical business model. By addressing the specific characteristics of individual patients as opposed to the 'average' characteristics of patients, companies can achieve improved patient outcomes and success rates. That said, this evolution requires advanced approaches to diagnostics, data analytics, and patient involvement.

The successful and large-scale delivery of integrated personalized medicines will require sophisticated integration in areas such as genetic research, digital healthcare, and innovative manufacturing solutions. A number of companies will emerge with considerable sustainable competitive advantages as a result of effective integration across these areas.

Adapting to Societal Norms

With the expansion of pharmaceutical companies, the growing incorporation of sustainability and ethical accountability is evident. Stakeholders are holding companies responsible for the sustainability of the supply chain, the Access to Medicines initiative, and Environmental Sustainability.

The interrelation between Brand Equity, Reputation, and Sustainability has made Corporate Social Responsibility (CSR) one of the most important elements of contemporary business. By being (i) Socially Responsible, (ii) Sustainable, and (iii) Patient-centered, companies cultivate trust and are able to most efficiently balance growth.

Agility and Innovation

With sustainability, patient-centered approaches and Corporate Social Responsibility (CSR) becoming a baseline expectation in modern business, trust and workforce retention are earned at the business. Agility, It is not just about the ability to adapt. It is about Innovation, Leadership, and Strategy.

Newer players in biotech are challenging long-established pharma businesses with innovative technologies and new business models.

The intersection of modern business practices and values with the core tenets of science in the pharmaceutical industry will always remain at the heart of the immense complexity and dynamics of the industry. Scaling innovative practices transcend mere increases in outputs. It necessitates resilient systems, optimized technology, and interconnected systems which in total provide for sustainable growth.

Success will come to those that can blend science and business strategy, and with patient expectations changing, those that can innovate, scale, and deliver value in all parts of the health care ecosystem will succeed.



Beyond Boundaries: The Convergence of **Science, Technology & Pharma**

The changes occurring in the pharmaceutical industry are redefining how innovations are imagined, constructed, and distributed. Focused on the rejuvenating combination of science, technology, and pharma, the changes create new models of cross-disciplinary collaboration for rapid advancements and betterment of the health of people.

An Integrated Approach to Innovation

Progress in the pharmaceutical industry was previously almost exclusively determined by the research conducted in laboratories. The focus has now shifted to innovation within an Integrated Approach to Innovation that encompasses the life sciences and the engineering, data sciences, and digital technology disciplines. The integration of these disciplines has fostered the development of more rapid, intelligent, and targeted processes for drug discovery and development.

The current pharmaceutical workforce comprises biologists, chemists, data scientists, software engineers, and almost every other specialized discipline that is required to address the complex challenges in healthcare.

Fueling the Change

The rapid advancement of technology, and more specifically artificial intelligence and machine learning, continues to significantly alter the drug discovery and development processes.

The identification of drug candidates, molecular behavior prediction, clinical trial design, and every other aspect that was previously time intensive, can now occur almost instantly compared to the time it used to take.

The sharing and analysis of data and combining of technologies such as advanced imaging and automation allows for laboratories to make improvements and increases in precision and throughput. These technologies allow laboratories and researchers to conduct and make more experiments with more speed and accuracy.

Robotic technology advances also provide laboratories to make improvements in the precision and throughput and to scale experiments to allow more tests and conduct more experiments.

Digital twin technology and simulation also allow scientists to replicate and predict outcomes of biological processes and systems without having to conduct an experiment. This technology allows the laboratory and researchers\ to mitigate and eliminate time, cost, and risk of the drug development process.

Technological advances are changing the redefining and changing the processes of the drug development.

From virtual compound screening to flexible, technology enabled and data driven clinical trials, every aspect of the life-cycle is incorporating technology in the laboratory.

Decentralized clinical trials, hybrid clinical trials, and continuous patient monitoring made possible by wearable technology and virtual monitoring, increase the involvement of patients, and improve the quality of the data captured. The integration of RWE data with clinical trial data provides more insight and increases the reporting of real effect of treatment.

Also, advanced analytics are enabling the implementation of adaptive clinical trials, which allow the real time revision of clinical trial objectives and procedures to improve the quality of patient outcomes.

Personalized and Precision Medicine

The integration of multiple technological advancements has led to the development of personalized medicine. Through the combination of digital health tools, bioinformatics, and genomics, stakeholders and pharmaceutical companies are now able to create tailored medicines. This is particularly true in the case of oncology, rare diseases, and several chronic conditions, and where traditional methods usually do not work.

Aside from enhancing positive results for patients, this change in the paradigm of medicine further enhances the value proposition of the therapies.

The Role of Startups and Innovation Hubs

Innovative hubs combined with startups are essential for the development of this convergence. These lean, tech-oriented companies are leading radical shifts in the older paradigms of the pharmaceutical industry. Startups are leading the way with AI drug discovery platforms, digital therapeutics, and more.

Big pharma has multiple partnerships with these newcomers, be it through public-private partnerships, incubators, accelerators, and venture capital partnerships. Through this model, large companies can create value to stay competitive, and startups can scale their solutions.

Data: The New Currency

Data, in today's converged landscape, is of immense importance.

The ability to provide valuable insights/innovations through the gathering, analyzing, and interpreting of extensive levels of biological and clinical data is what helps drive further advancements/innovations. The rapid analytical and interpretational ability of one organizational unit is not the case for those of data privacy, protection, and standardization.

Risk and trust mitigation through Customer Data Governance Platforms is an investment in reputation, and risk mitigation through data privacy protection services is sacrificing reputation/cost. Prevention through compliance structures is not an option.

Outlook: Problems to come

The integration of technology, science, and pharmaceuticals presents unique opportunities and problems. It is not an easy task to integrate various systems, lead interdisciplinary teams, and integrate different cultural organizations.

In addition, the rapid pace of technological change requires continuous retraining of employees. Organizations must provide the infrastructure necessary for employees to continue their education in order to keep pace with technological change.

Regarding the rapid emergence of AI and digital therapeutics, there is a lack of clarity on the regulation of rapid technological change. To leverage the intertwined problems of Technology and the Workforce, the regulatory challenges must be resolved and optimized towards global convergence.

The Evolution of a Borderless Industry

In the United States, the convergence of science, tech, and pharma is creating a more integrated and patient-centered future.

The discrete fields of health system innovation are no longer distinct and are now characterized by a more whole systems approach.

In this new era, the ability to change and the effective use of technology will be important. The businesses that lead this convergence will be the ones who radically change the industry and enhance the healthcare system.

Conclusion

The term "Beyond Boundaries" does not apply to merely an abstract idea, it embodies the emerging reality in the pharmaceutical industry.

The new ecosystems in the pharmaceutical industry are limitless as a result of the integration of science and technology with pharmaceutical innovation

The leaders of the industry clearly define the challenges. They need to remove the silos, and the barriers to industry crossovers and technological collaboration, and transform the potential of the industry into reality. Those leaders will determine the next set of innovations for the world by providing high quality, rapid, and efficient health care solutions.

Mixing Systems in **Biopharma Applications**

Innovative Single-Use Solutions for **Upstream and Downstream Processing**

The importance of mixing systems in modern biopharmaceutical manufacturing is undeniable; they play a key role in managing sterility, ensuring the consistency of products, and aiding in the efficiency of manufacturing processes. As the industry rapidly shifts towards single-use technologies, mixer bag systems have emerged as a novel and dependable option for all upstream and downstream processes.

The biopharmaceutical and single-use disposable industries have engineered systems specifically designed for them by crafting these systems in cleanroom facilities (ISO Class 7 / ISO Class 8), where a high degree of quality is maintained for every aspect, from the selection of the initial materials to the fulfillment of the final product.

Key features & benefits

1. Customized engineering for individual process applications
2. Built-in precision impeller for mixing that is consistent and uniform
3. Enhanced burst strength for durability and operational safety
4. Pressure leak testing and integrity guaranteed
5. Enhanced protection of product molecules and parts
6. Simplified inlet and outlet connections
7. Multiple options: 50L | 100L | 200L | 500L | 1000L

Applications in Biopharma
Upstream Processing

Single-use mixing systems play a vital role in:

Here is a new version of the text provided:

Media Preparation
Ensures the uniform dissolution of powdered nutrients in WFI, which is directly linked to improved cell growth and productivity.

Buffer Preparation
Ensures precise and uniform mixing for the pH adjustment during cell culture and fermentation.

Cell Culture Applications
Guarantees the sterility and uninterrupted consistency of media preparation and storage.

Process & Fluid Transfer
Allows for safe and uncontaminated transfer of process liquids.

Downstream Processing
Mixer systems are also essential in:
Buffer & Reagent Preparation
Mixing helps in chromatographic and filtration operations.

Process Intermediates
Used in the purification steps to hold and mix intermediate bulk solutions.

Virus Inactivation
Ensures consistent interaction between the product and the inactivation agents.

Final Formulation
Mixing of APIs and excipients is done in a controlled and gentle manner to reduce shear stress and protein aggregation.

Fill-Finish Operations
Ensures the mixture is homogeneous prior to sterile filling into vials or syringes.

Compliance & Certifications

1. Designed for compliance with international regulators:
2. ISO 11137 – Sterilization Validation
3. USP <87> – Biological Reactivity (In Vitro)
4. USP <88> – Biological Reactivity (In Vivo)
5. USP <661> – Plastic Packaging Systems
6. Extractables & Leachables Studies

These certifications provide assurance for the safety of materials, biocompatibility, and market clearance in compliance with global regulations.

The Role of Advanced Polymer Solutions

Maintaining sterility and chemical compatibility is critical, and high-performance polymer components like silicone tubing, single-use assemblies, gaskets, and custom molded parts are crucial in achieving this.

Ami Polymer offers cutting-edge polymer solutions for the biopharmaceutical industry, enabling safe, scalable, and compliant mixing technologies.

By Sreedhar Chirra
Assistant Manager **(Business Development)**

Flat film degasser offers **superior efficiency** and **improved compatibility**

Biotech **Fluidics** has announced a major innovation in fluidic degassing with the launch of their high performance **DEGASi® Flat Film in-line degasser.**



High performance **DEGASi®** Flat Film in-line degasser and vacuum controller

Utilizing specialized flat film, rather than traditional tubing, to remove dissolved gases, the system provides superior degassing efficiency and improved compatibility with viscous fluids and almost any organic solvent.

Featuring a chemically inert, metal-free flow path - **DEGASi®** Flat Film degassers are not only biocompatible but are also highly sustainable as their PFAS content is reduced to one tenth of standard tubular degassers.

The increased degassing efficiency of DEGASi® Flat Film degassers enables the use of a higher vacuum set point for degassing of volatile solvents, while minimizing evaporation of mobile phase into the lab atmosphere.

Available as a stand-alone unit, or as an OEM component, the extremely low flow restriction offered by **DEGASi®** Flat Film degassers enables the use of up to six chambers in series to cover higher flow rates in HPLC and process applications without loss of degassing efficiency.

Compact in profile - **DEGASi® Flat** Film degassers units use the latest Degasser Vacuum Control unit incorporating fifth generation StabiliX pumps that deliver extraordinary stable vacuum and lower acoustic profile all combined with an unmatched trouble-free long operational lifetime.

For further information please visit https://biotechfluidics.com/products/degassing-debubbling/degasi-inline-degassers/degasi-flatfilm/ or contact Biotech Fluidics on + 46 300 56 91 80 / + 1-612-703-5718 / info@biotechfluidics.com.

Biotech Fluidics is a leading supplier of fluidic system solutions, liquid transfer components, degassing systems, and innovative laboratory technology to instrument developers, manufacturers, and distributors all around the world. The company's mission is to empower its customers by designing and assembling unique products, being a dependable partner, offering first-class service, in-depth knowledge, and offering advanced technical support for all the items it provides. For further information - www.biotechfluidics.com

STARe Software: The Standard in **Thermal Analysis**

Maximum Flexibility

High Quality Results with Less Effort

Thermal analysis is a well-established analytical method that is widely used in many different fields. It provides laboratories with valuable results and new information in quality assurance and control, process and product development, and research. Many problems can be solved by using a combination of different thermal analysis techniques.



Features and benefits of the STARe Excellence METTLER TOLEDO software:

- **Unlimited evaluation possibilities –** provides enormous flexibility
- **Reliable automation –** high sample throughput with automatic evaluation dramatically improves efficiency
- **Unique integrated database solution –** guarantees the highest level of data security
- **Solid compliance –** supports 21 CFR Part 11 user level management and electronic signatures
- **Modular concept –** tailor-made solutions for current and future needs
- **Easy and intuitive OneClick™ operation –** saves time in training and in daily use
- **Timesaving FlexCal™ calibration –** for more accurate measurement results
- **State-of-the-art LIMS integration –** guarantees seamless processes from external tasks
- to measure evaluation and result assessment

Unparalleled Evaluation Possibilities

The Right Solution for Every Measurement

STARe is the benchmark for flexible evaluation. A complete software package and expert evaluation possibilities are the basis for the correct interpretation of measurement results. The STARe evaluation software combines application-specific evaluation tools optimized for thermal analysis users with the flexibility of a superior layout program whose functionality sets no limits to individual creativity.

- **Automation for enhanced productivity –** In routine operation, you can automate everything from the measurement to the evaluation and final result assessment
- **Simple operation –** STARe functionality is readily accessible from the software's intuitive ribbon interface. Features such as **OneClick™**, multiple curve handling and available options like Quality Control or the Reference Library simplify routine work.

- **Modular concept –** The flexible STARe software consists of the base software and a large number of application-specific options to satisfy your current and future requirements

STARe software by **METTLER TOLEDO** sets the standard in thermal analysis by combining flexibility, automation, precision, and user-friendly operation. Its modular architecture, comprehensive features, and compliance support make it an indispensable tool for laboratories aiming to achieve high-quality thermal analysis results with enhanced productivity and reliability.

About METTLER TOLEDO

METTLER TOLEDO is a leading global manufacturer of precision instruments. The Company is the world's largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions for several related analytical instruments and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development. In addition, the Company is the world's largest manufacturer and marketer of metal detection systems used in production and packaging. Additional information about **METTLER TOLEDO** is available at www.mt.com.

Visit us: Thermal Analysis Software | TA Software

Email us at – sales.sales@mt.com

Call us toll-free at – 1800 22 8884 & 1800 1028 460

ADVENT

Readily Available in Gram to Kg scale*:

Name of Fmoc Amino Acid	CAS No.
Fmoc-Asn-OH	71989-16-7
Fmoc-Phe-OH	35661-40-6
Fmoc-Pro-OH	71989-31-6
Fmoc-Gln-OH	71989-20-3
Fmoc-Gly-OH	29022-11-5
Fmoc-Ala-OH	35661-39-3
Fmoc-ß-Ala-OH	35737-10-1
Fmoc-Cys(Trt)-OH	103213-32-7
Fmoc-Gly-Gly-OH	35665-38-4
Fmoc-ß-Ala-Gly-OH	NA
Fmoc-ß-Ala-Cys(Trt)-OH	NA
Fmoc-Gly-Gly-Gly-OH	170941-79-4

*The list is not exhaustive and new Fmoc & other substituted Amino Acids & Short Peptides are being added to the ever-expanding basket continually. Kindly send your queries to sales@adventchembio.com

Fmoc Amino Acids and short Peptides : Advanced Building Blocks for Peptide Synthesis

Highest Purity

Customised combinations of amino acids as per end application

Absence of related interfering & isomeric impurities

Available in gm to Kg scale

Advent Chembio Pvt. Ltd.®
(ISO 9001:2015, ISO 14001:2015 Certified)
W-279, TTC Industrial Area, MIDC, Rabale, Navi Mumbai-400 701, Maharashtra, INDIA.
+91 7777084837 sales@adventchembio.com www.adventchembio.com

Putting the Pressure On: Proven Flow Measurement Where Failure is Not an Option

In high-pressure fluid systems, inaccuracy is more than a measurement problem - it's a performance, safety, and cost risk. From hydraulic power units to oilfield chemical injection skids, reliable flow data under extreme pressure is essential to keeping critical systems running efficiently and safely.

Titan Enterprises designs its high-pressure Oval Gear flow meters specifically for environments where operating conditions push components to their limits. These meters deliver stable, repeatable measurement across extreme pressures, fluctuating viscosities, and chemically aggressive fluids - conditions that quickly expose the weaknesses of less robust technologies.

Why High-Pressure Flow Measurement Demands More

Hydraulic and fluid power systems operate at pressures high enough to magnify even minor inefficiencies. In applications such as additive injection, lubrication monitoring, or hydraulic actuation, inaccurate flow measurement can lead to overdosing, premature wear, energy loss, or unplanned shutdowns.

This is why positive displacement technologies, particularly oval gear flowmeters, continue to be widely specified in high-pressure systems. Their ability to directly measure volume, independent of flow profile or turbulence, makes them especially effective where precision and repeatability are non-negotiable.

Industries that rely on high-pressure hydraulic systems include aerospace, offshore energy, marine propulsion, heavy equipment, and high-performance automotive engineering. In oil and gas operations, the requirement is even more stringent, with flow meters expected to perform reliably in continuous service while exposed to high pressure, high viscosity fluids, and aggressive chemicals.

Designing for Pressure Starts with Testing

A component's pressure rating is only meaningful if it has been proven. Pressure testing is a critical stage in validating the mechanical integrity, safety, and long-term reliability of hydraulic components.

PR159-Putting-the-Pressure-on

Titan Enterprises has a dedicated in-house pressure test facility to validate every aspect of its oval gear flow meter designs. By pressure testing during manufacturing and development, Titan can identify potential failure points early, verify compliance with safety standards, and ensure each product is fit for purpose before deployment.

In-House Capability That Goes Beyond Compliance

Titan's Hydratron pressure test rig can test flow meters at pressures up to **1,400 Bar**, exceeding the maximum operating pressure of its current product range. This allows Titan not only to qualify production meters, including models rated up to **950 Bar**, but also to push designs beyond their nominal limits during development.

This capability has accelerated product refinement, enabling improvements in gear geometry, material selection, and platform standardization. The result is a more interchangeable, robust product range and the potential to increase the maximum operating pressure of Titan's standard oval gear flow meters by approximately 50%.

The test facility also supports advanced R&D work, including cavitation simulation and the evaluation of new materials for future high-pressure applications.

Technical Insight: Flow Measurement Under Extreme Pressure - Why oval gear technology excels in high-pressure systems

Direct Volume Measurement
Unlike inferential flow technologies, oval gear meters directly measure displaced volume. This makes them inherently insensitive to changes in flow profile, turbulence, or pulsation - common issues in high-pressure hydraulic circuits.

Accuracy Improves with Viscosity
As liquid viscosity increases, internal slip is reduced. Titan's oval gear meters leverage this effect, improving accuracy from approximately ±1% to as low as ±0.1% of reading at higher viscosities - ideal for oils, additives, and lubricants.

Pressure-Proven Design

- Standard operating range: 10 bar to 950 Bar
- Pressure tested in-house up to 1,400 Bar
- Design validation supports potential 50% increase in maximum operating pressure across standard platforms

Engineered for Harsh Media
Compatible with chemically aggressive fluids and additives used in oil and gas, petrochemical processing, and hydraulic power systems. Material options are selected and pressure-tested to ensure long-term chemical resistance and dimensional stability.

Repeatability Where Control Matters
With 0.1% repeatability, Titan's proprietary oval gear design supports precise dosing, additive injection, and consumption monitoring - critical for closed-loop control systems.

Performance Where It Counts

Titan's Oval Gear flowmeters are designed to improve accuracy as viscosity increases, achieving measurement performance from approximately ±1% down to ±0.1% of reading. This characteristic makes them particularly suited to high-pressure additive injection and lubrication systems, where fluids often fall outside the operating envelope of other meter technologies.

With pressure ratings from 10 bar to 950 bar, operating temperatures up to 150°C, and intrinsically safe ATEX-approved options, the meters are engineered for long service life in hazardous and demanding environments.

Built Around the Application

Beyond its standard flow measurement products, Titan works closely with OEM customers to develop customised flow measurement solutions tailored to specific pressure, viscosity, and chemical compatibility requirements.

This collaborative approach ensures flow meters integrate seamlessly into complex systems across oil and gas, petrochemical processing, marine, and emerging energy sectors.

By combining proven positive displacement technology with rigorous pressure validation and in-house development capability, Titan Enterprises delivers flow measurement solutions that perform reliably when systems are operating under pressure and when there is no margin for error.

More information can be found at www.flowmeters.co.uk

About Titan Enterprises

With over four decades of expertise in liquid flow measuring solutions, Titan Enterprises designs and manufactures high-performance flowmeters for OEMs, industrial and laboratory applications. Known for innovation, reliability, and a collaborative engineering approach, Titan supports customers worldwide in precision flow measurement challenges.

For more information please contact:

Media: Mrs Samantha Hannay,
Marketing Manager,
Titan Enterprises
+44 (0)1935 812790 / marketing@flowmeters.co.uk

Eppendorf launches **SpinPro®** centrifuge series for streamlined life science research

Eppendorf, a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world, today announced the commercial launch of the **SpinPro® 6 R centrifuge**, the first in the Company's new range of SpinPro floor-standing and benchtop centrifuges.

With an advanced user-interface and ergonomic operation, the **SpinPro 6 R provides** a flexible, and scalable solution for sample separation.

Effortless Every Time – Redefine Centrifugation with SpinPro® 6 R

Building on Eppendorf's established range of benchtop centrifuges, the **refrigerated SpinPro 6 R benchtop** centrifuge offers additional smart features to streamline workflows including new rotors with universal adapters.

These rotors can be interchanged within various models of the upcoming SpinPro line, reducing inventory and minimizing costs.

With a wide range of compatible vessels, the rotors can support applications such as cell culture harvesting, processing of biological samples and isolation of proteins across pharma, biotech, food, and agriculture sectors.

Radio Frequency Identification (RFID) chipped rotors enable instant recognition, increasing safety for both samples and users. All new fixed-angle rotors are equipped with **Eppendorf QuickLock®** Pro lids for fast and easy one-handed operation.

Designed with ergonomics in mind, the SpinPro 6 R is simple to use and easily integrated into existing workflows.

Its intuitive software and adaptive 7-inch touch-based display ensure straight-forward set up, while the one-touch operation electric lid drive allows for ergonomic interaction with the device.

The **SpinPro 6 R is ACT 2.0** labelled, using **CO2–based cooling technology** without **F-gases** and full transparency on consumption, production, and sourcing, to contribute to **laboratory environmental targets.**

Dr. Tim Schommartz, Global Marketing Manager at Eppendorf SE said: "I see the new SpinPro 6 R centrifuge as a great addition for busy labs worldwide. It combines powerful performance with our latest sustainable CO2-based cooling technology, intuitive Eppendorf QuickLock® Pro lids, and advanced compliance features such as documentation and seamless LIMS integration.

The SpinPro range is all about making centrifugation more convenient, more reliable, and more efficient – allowing scientists to concentrate on their research!"

Badrinarayanan, Product Marketing Manager at **Eppendorf India**, said: "Eppendorf proudly introduces the SpinPro 6 R centrifuge, engineered to elevate laboratory efficiency and compliance. Featuring innovative CO_2-based sustainable cooling, Eppendorf QuickLock® Pro lids, and advanced compliance capabilities such as documentation and seamless LIMS integration. The SpinPro 6 R sets a new standard for reliability and operational excellence. This next-generation SpinPro range minimizes risk and error, empowering scientists to accelerate research with confidence while supporting sustainability and regulatory requirements."

For more information on the SpinPro 6 R, visit: www.eppendorf.link/spinpro6r

Alembic Pharmaceuticals Reports First Prescription Sale of Pivya® (pivmecillinam) Following US Commercial Launch

Alembic Pharmaceuticals Limited ("Alembic") today announced the first prescription-based sale of **Pivya® (pivmecillinam) tablets**, an oral prescription antibiotic, following its recent commercial launch in the United States of America (US). Pivya® is Alembic's first branded pharmaceutical product in the US and is being marketed through Alembic Therapeutics LLC, a step-down wholly owned subsidiary of Alembic.

Pivya® represents a first-line oral antibiotic option for the treatment of uncomplicated urinary tract infections (uUTIs) in women. The segment has seen limited new product introductions for more than a decade, creating an opportunity for a clinically established therapy with a strong safety and efficacy profile.

Alembic
Touching Lives over 100 years

Commenting on the milestone, **Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited**, said: "The commercial launch of Pivya® marks an important milestone for Alembic as we enter the US branded pharmaceuticals market. What began as a strategic acquisition has now translated into a commercial presence in the specialty prescription segment.

Pivya® represents the first step in Alembic's strategy to build a focused branded specialty portfolio in the US, enabling us to participate in a large and stable therapeutic category with a clinically established and differentiated product. Over time, we intend to leverage this platform to build a broader branded portfolio in the US market."

Market Context

Uncomplicated urinary tract infections remain among the most common bacterial infections in women in the US, resulting in a significant volume of outpatient antibiotic prescriptions annually.

With increasing emphasis on appropriate antibiotic stewardship and the need for effective first-line therapies, clinically established agents such as pivmecillinam are expected to play an important role in the management of uncomplicated urinary tract infections.

The therapeutic category represents a large and stable market, accounting for approximately 30 million prescriptions annually in the US.

About Pivya® (pivmecillinam)

Pivya® contains pivmecillinam, a beta-lactam antibacterial agent with a long history of clinical use internationally. Pivya® is a penicillin-class antibacterial indicated for the treatment of female patients (18 years of age and older) with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Pivya® and other antibacterial drugs, Pivya® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Commercial Strategy:

Alembic has established an initial sales footprint across key territories in the US, with each territory focusing on high-prescribing physicians in women's health and engaging a targeted base of prescribers. The Company plans a phased expansion of field force as prescription momentum builds, supported by targeted physician education and market access initiatives.

Strategic Context:

Alembic continues to expand its presence in the US, one of the world's largest pharmaceutical markets, through a balanced approach across generics, specialty products, and branded pharmaceuticals. The launch of Pivya® represents an important step in building a focused branded business platform in the US, complementing the Company's established generics franchise.

Alembic remains committed to disciplined investments that support sustainable growth and long-term value creation.

About Alembic Therapeutics LLC

Alembic Therapeutics LLC is committed to providing high-quality prescription medicines to support patient care and healthcare delivery. The launch of Pivya® reflects our ongoing focus on Quality, Reliability, and Access.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Its brands, marketed through a field force of over 5500+, are well recognized by doctors and patients.

Information about the Company can be found at www.alembicpharmaceuticals.com; (Reuters:ALEM.NS) (Bloomberg:ALPM) (NSE:APLLTD) (BSE:533573)

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg.

Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lamictal ODT Orally Disintegrating Tablets, 25 mg, 50 mg, 100 mg, and 200 mg, of GlaxoSmithKline LLC.

Lamotrigine is indicated as adjunctive therapy in patients aged 2 years and older for: i) partial-onset seizures, ii) primary generalized tonic-clonic (PGTC) seizures and iii) generalized seizures of Lennox-Gastaut syndrome. It is also indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED).

Lamotrigine is indicated for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. Refer label for a detailed indication.

Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg, have an estimated market size of US$ 27 million for twelve months ending December 2025 according to IQVIA.

Alembic has a cumulative total of 235 ANDA approvals (216 final approvals and 19 tentative approvals) from USFDA.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.

Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5500 are well recognized by doctors and patients.

Information about the Company can be found at www.alembicpharmaceuticals.com; (Reuters:ALEM.NS) (Bloomberg:ALPM) (NSE:APLLTD) (BSE:533573)

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Efinaconazole Topical Solution

Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Efinaconazole Topical Solution, 10%.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Jublia Topical Solution, 10%, of Bausch Health Americas, Inc. (Bausch). Efinaconazole Topical Solution is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes. Refer label for a detailed indication.

Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification. Efinaconazole Topical Solution, 10%, has an estimated market size of US$ 500 million for twelve months ending December 2025 according to IQVIA.

Alembic has a cumulative total of 234 ANDA approvals (215 final approvals and 19 tentative approvals) from USFDA.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India,

Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5500 are well recognized by doctors and patients.

Information about the Company can be found at www.alembicpharmaceuticals.com; (Reuters:ALEM.NS) (Bloomberg:ALPM) (NSE:APLLTD) (BSE:533573)

Aurobindo Pharma Shares Soar 3% as Arm Secures VAI from USFDA

The USFDA investigated the API manufacturing facility in Telangana from 1 December to 12 December 2025.

Shares of Aurobindo Pharma Ltd soared 3% on 20 March after the company announced that its wholly owned subsidiary, Apitoria Pharma Pvt Ltd, has acquired a 'Voluntary Action Indicated' (VAI) classification from the US Food and Drug Administration (USFDA) for its Unit-V production facility.

The USFDA investigated the API manufacturing facility in Telangana from 1 December to 12 December 2025, and issued a Form 483 with three observations.

Subsequently, the unit obtained an Establishment Inspection Report (EIR) designating the facility as VAI, indicating that the inspection was completed.

The VAI designation indicates that, while certain observations were made during the inspection, they do not merit regulatory or enforcement action by the USFDA. The development signifies the end of the facility's inspection process.

Following an inspection earlier this week, the USFDA designated another of the company's subsidiaries, Eugia Pharma Specialities Ltd, as 'Official Action Indicated' (OAI).

In the December quarter, Aurobindo Pharma's net profit increased by 7.5% to Rs 909.8 crore from Rs 846 crore. This included a one-time cost of Rs 65 crore due to a change in the labour code.

The revenue for the quarter increased by 8.4% YoY to Rs 8,646 crore from Rs 7,979 crore in Q3FY25. EBITDA increased 12.4% to Rs 1,773.6 crore from Rs 1,577.5 crore last year. The EBITDA margin rose to 20.5% from 19.8% in the same period last year.

At 12:24 pm, the shares of Aurobindo Pharma were trading 3.05% higher at Rs 1,285.60 on NSE.

USFDA Greenlights Bristol Myers Squibb's Opdivo® Combo for First-Line Hodgkin Lymphoma

The U.S. Food and Drug Administration has approved **Opdivo® (nivolumab)**, developed by Bristol Myers Squibb, in combination with chemotherapy for the first-line treatment of advanced classical Hodgkin lymphoma.

This approval marks a significant advancement in immuno-oncology, providing a new standard treatment option for patients with stage III or IV disease.

The approved regimen combines Opdivo® with **AVD chemotherapy**, delivering improved progression-free survival outcomes compared to conventional therapies. Clinical data demonstrated that patients receiving this combination experienced better disease control and reduced risk of relapse, positioning the therapy as a preferred frontline option.

Opdivo® functions as a **PD-1 immune checkpoint inhibitor**, enhancing the body's immune system to identify and attack cancer cells more effectively.

Its expanding role across multiple cancer types highlights its importance as a cornerstone drug in modern oncology treatment strategies.

The FDA's decision also includes confirmation of long-term safety and efficacy data, strengthening confidence in its broader clinical application. The approval reflects the continued evolution of immunotherapy-based treatment approaches.

With this milestone, Bristol Myers Squibb reinforces its leadership in oncology innovation, offering patients more effective and targeted treatment solutions for complex hematologic cancers.

Novo Nordisk Secures USFDA Approval for Higher-Dose Wegovy® in Obesity Treatment

The U.S. Food and Drug Administration has approved a higher-dose version of **Wegovy® (semaglutide)** developed by Novo Nordisk, marking a major step forward in obesity management. The new 7.2 mg dose is designed to deliver enhanced weight loss outcomes for patients requiring more intensive therapy. Clinical trials demonstrated that patients treated with the higher-dose Wegovy® achieved **over 20% average weight reduction**, significantly improving outcomes compared to earlier dosing regimens. This positions the therapy among the most effective pharmacological solutions for obesity currently available.

Wegovy® works as a **GLP-1 receptor agonist**, helping regulate appetite, reduce caloric intake, and support sustainable weight loss. Its mechanism mimics natural hormones responsible for satiety, making it highly effective in long-term weight management.

The newly approved formulation will be delivered through a **user-friendly single-dose injection pen**, enhancing patient convenience and adherence. This aligns with the growing trend toward self-administered therapies in chronic disease management.

As obesity continues to pose a global health challenge, this approval strengthens Novo Nordisk's leadership in metabolic disease therapeutics and expands access to highly effective treatment options.

Johnson & Johnson's **Icotyde®** Receives USFDA Approval for Psoriasis Treatment

The U.S. Food and Drug Administration has approved **Icotyde®**, an innovative oral therapy developed by Johnson & Johnson, for the treatment of moderate-to-severe plaque psoriasis. This approval introduces a convenient alternative to injectable biologics, improving patient accessibility and compliance.

Icotyde® targets the **IL-23 inflammatory pathway**, a key driver of psoriasis symptoms. By selectively inhibiting this pathway, the drug provides superior skin clearance and long-term disease control compared to existing treatment options.

Clinical trials have shown strong efficacy and safety profiles, positioning Icotyde® as a potential blockbuster drug in the dermatology segment. Its once-daily oral dosing offers a major advantage over injectable therapies, which often require clinical administration.

Beyond psoriasis, the drug is being explored for multiple inflammatory conditions, including **psoriatic arthritis and inflammatory bowel diseases**, indicating strong pipeline expansion potential.

This approval reflects the growing shift toward targeted, patient-friendly therapies in immunology and reinforces Johnson & Johnson's leadership in innovative healthcare solutions.

USFDA Expands Rare Disease Treatment Portfolio with Yuviwel™ and Loargys™ Approvals

The U.S. Food and Drug Administration has approved multiple novel therapies in 2026, including **Yuviwel™ (navepegritide)** and **Loargys™ (pegzilarginase)**, aimed at addressing rare and underserved medical conditions. These approvals underscore the agency's commitment to accelerating innovation in critical therapeutic areas.

Yuviwel™ has been approved for the treatment of **achondroplasia**, a genetic disorder affecting bone growth in children. The therapy is expected to significantly improve growth outcomes and quality of life for pediatric patients.

Loargys™ targets **Arginase 1 Deficiency**, a rare metabolic disorder that can lead to severe neurological complications. The approval provides a much-needed treatment option for patients with limited therapeutic alternatives.

These approvals highlight the FDA's increasing focus on **rare disease drug development**, encouraging pharmaceutical companies to invest in niche but high-impact therapeutic areas.

Overall, the expansion of the novel drug pipeline reflects a broader regulatory effort to bring life-changing treatments to patients faster while maintaining stringent safety and efficacy standards.

USFDA Clears **Scino Pharm** Taiwan's Generic Glatiramer Acetate for MS Treatment

The U.S. Food and Drug Administration has approved a **generic version of glatiramer acetate injection** developed by ScinoPharm Taiwan for the treatment of relapsing forms of multiple sclerosis (MS). This approval is expected to significantly improve patient access to affordable therapies.

ScinoPharm

Glatiramer acetate is a widely used immunomodulatory drug that helps reduce inflammation and prevent nerve damage in MS patients. The availability of a generic version is likely to lower treatment costs and increase accessibility for a broader patient population.

The approval is particularly notable as it involves a **complex injectable generic**, requiring rigorous evaluation to ensure bioequivalence with the original branded product. This demonstrates the FDA's capability to assess advanced pharmaceutical formulations.

The introduction of this generic drug is expected to enhance competition within the MS treatment market, driving down prices and improving healthcare affordability.

This development aligns with ongoing regulatory efforts to promote generic drug adoption, ensuring that patients receive effective treatments at reduced costs.

Cytokinetics Secures USFDA Approval for Myqorzo™ in Hypertrophic Cardiomyopathy

The U.S. Food and Drug Administration has approved **Myqorzo™ (aficamten)**, developed by Cytokinetics, for the treatment of **obstructive hypertrophic cardiomyopathy (HCM)**. This approval represents a major advancement in the management of this rare cardiovascular condition.

Myqorzo™ is a **cardiac myosin inhibitor** that works by reducing excessive contraction of the heart muscle, improving blood flow and reducing symptoms such as shortness of breath and fatigue. Clinical trials have shown significant improvements in patient outcomes.

The drug is expected to provide a strong alternative to existing therapies, offering improved safety and convenience for long-term disease management. It also marks Cytokinetics' first FDA-approved product, strengthening its position in the cardiovascular drug market.

Due to safety considerations, the therapy will be distributed under a **Risk Evaluation and Mitigation Strategy (REMS)** program, ensuring proper monitoring and controlled usage.

With limited treatment options currently available for HCM, this approval is a major breakthrough, offering new hope to patients and reinforcing innovation in rare disease therapeutics.

Avio Smart Market Stack, **Huwel Lifesciences** to Launch Patented Molecular Diagnostic Products Across Healthcare Segments

Avio **Smart Market Stack Limited (ASMS)**, formerly known as **Bartronics India Limited,** has initiated an expanded **collaboration with Huwel Lifesciences to introduce a range of patented molecular diagnostic products across multiple healthcare segments in India.**

The development follows the recently signed Shareholders' Agreement between the two companies, under which they aim to j**ointly scale advanced diagnostic technologies and bring them to institutional and healthcare markets across the country.**

Huwel Lifesciences has developed multiple patented diagnostic technologies and is building a strong pipeline of new products, with several additional patents and platforms currently under development. The company's capabilities **span RT-PCR diagnostic kits, point-of-care molecular testing devices, and disease detection panels. Research, assay development, and manufacturing are carried out within Huwel's own facilities.**

Positioning itself as a fully indigenous diagnostics innovator, Huwel is among the few molecular diagnostics companies in India with the capability to design, develop, and manufacture most components of its diagnostic platforms in-house, aligning with the **Government of India's "Make in India" initiative.**

India represents one of the largest markets globally for infectious disease diagnostics. National health programs and institutional healthcare networks together conduct tens of millions of diagnostic tests annually for diseases such as tuberculosis, HIV, hepatitis, and other infectious conditions. The diagnostics market for these diseases alone is estimated to exceed ₹5,000 crore annually in India.

Huwel's molecular diagnostic solutions are designed to **enable rapid and cost-efficient tuberculosis detection** using **open RT-PCR systems,** allowing **tests to run on RT-PCR laboratory infrastructure** that was widely deployed across the country during the COVID-19 pandemic.

This approach enables scalable public health testing without requiring significant new infrastructure investments.

The company's tuberculosis molecular diagnostic platform has already received the necessary regulatory approvals and validations.

Building on the same technology platform, Huwel has also **developed molecular diagnostics for HIV, HPV-based cervical cancer screening, antimicrobial resistance (AMR) surveillance, hepatitis, and several other infectious diseases, using scalable open RT-PCR systems suitable for large-scale testing.**

As part of the **collaboration, Avio Smart Market Stack will support the go-to-market strategy, institutional engagement, and commercialization of these technologies by leveraging its institutional relationships, digital infrastructure capabilities, and experience in executing large-scale programs.**

Commenting on the collaboration, **Mr. Vidhyasagar Reddy, Managing Director, Avio Smart Market Stack Limited**, said: *"India has a significant opportunity to strengthen its public health infrastructure through indigenous diagnostic innovation. Our collaboration with Huwel Lifesciences brings together advanced molecular diagnostic technologies and our institutional market access capabilities. By leveraging the extensive RT-PCR infrastructure established across the country during the pandemic, we aim to accelerate the availability of rapid, accurate, and affordable diagnostics for diseases such as tuberculosis, HIV, hepatitis, and other infectious conditions. This partnership aligns with our broader vision of supporting scalable health-tech solutions that can improve healthcare access across India."*

Over the coming years, ASMS and Huwel expect to introduce multiple diagnostic product lines across different disease segments, expanding the availability of indigenous molecular diagnostics across government health programs, hospital networks, diagnostic laboratories, and private healthcare providers.

About Avio Smart Market Stack Limited (formerly Bartronics India Limited)

Avio Smart Market Stack Limited has strategically expanded into the high-growth health-tech sector, supporting the development and commercialization of innovative diagnostic technologies aimed at improving access to affordable healthcare across India. Alongside this, the company is building what it aims to become India's largest unified rural operating system, integrating financial inclusion, agriculture, rural commerce, and climate solutions to digitally empower farmers and underserved communities across the country.

Pfizer Announces $1 Billion Expansion to Strengthen Global Manufacturing Network

Pfizer has announced a **$1 billion investment** to expand its global manufacturing capabilities, reinforcing its commitment to supply chain resilience and large-scale drug production. The expansion will focus on upgrading facilities in the United States and Europe, with an emphasis on biologics and next-generation therapeutics.

The company aims to enhance production capacity for **mRNA-based vaccines and specialty medicines**, building on the infrastructure developed during the COVID-19 pandemic. This strategic move is expected to improve response times for future global health emergencies while ensuring consistent supply of critical medicines.

Pfizer's investment also includes the adoption of **advanced manufacturing technologies**, such as automation, digital monitoring, and AI-driven quality control systems. These upgrades will enable higher efficiency, reduced operational costs, and improved product consistency across its facilities.

In addition, the expansion is expected to create **thousands of new jobs**, supporting local economies and strengthening the pharmaceutical manufacturing workforce. The company has emphasized sustainability, incorporating energy-efficient processes and reduced carbon emissions into its new facilities.

This initiative reflects a broader industry trend toward **localized and resilient supply chains**, positioning Pfizer as a leader in future-ready pharmaceutical manufacturing and global healthcare preparedness.

Merck Acquires Biotech Firm to Accelerate Oncology Innovation

Merck & Co. has announced the acquisition of a promising biotechnology company focused on **next-generation cancer therapies**, in a deal valued at several billion dollars. This strategic move is aimed at strengthening Merck's already robust oncology pipeline.

The acquisition brings access to **novel immunotherapy platforms and early-stage drug candidates**, which are expected to complement Merck's flagship cancer drug portfolio. The company plans to accelerate clinical development programs and bring innovative treatments to market faster.

Merck's leadership highlighted that the deal aligns with its long-term vision of **expanding precision medicine and targeted therapies**, particularly in areas with high unmet medical needs. The integration of advanced research capabilities is expected to enhance its R&D productivity.

The biotech firm's expertise in **AI-driven drug discovery and biomarker identification** will further support Merck's innovation strategy. This combination of technology and science is anticipated to improve clinical success rates and reduce development timelines.

This acquisition underscores the ongoing consolidation trend in the pharmaceutical industry, where large companies are increasingly partnering with or acquiring biotech innovators to maintain competitive advantage.

Roche Enters Multi-Year AI Partnership to Accelerate Drug Development

Roche has entered into a **multi-year strategic partnership with a leading artificial intelligence company** to revolutionize drug discovery and development processes. The collaboration aims to leverage AI for faster identification of drug candidates and improved clinical outcomes.

Through this partnership, Roche will integrate **machine learning algorithms and big data analytics** into its research workflows. This will enable scientists to analyze complex biological datasets more efficiently and identify promising therapeutic targets with higher precision.

The collaboration is expected to significantly reduce **drug development timelines and costs**, addressing one of the biggest challenges in the pharmaceutical industry.

By improving early-stage decision-making, Roche aims to increase the success rate of clinical trials.

Additionally, the partnership will focus on **personalized medicine**, using AI to develop targeted therapies tailored to individual patient profiles. This approach aligns with the growing demand for precision healthcare solutions.

This initiative highlights the increasing convergence of **pharmaceutical science and digital technology**, positioning Roche at the forefront of innovation in data-driven drug development.

Novartis Completes Sandoz Spin-Off to Focus on Innovative Medicines

Novartis has officially completed the spin-off of its generics and biosimilars division, **Sandoz**, marking a major strategic transformation. The move is designed to allow Novartis to focus entirely on its high-margin innovative medicines business.

The separation enables both companies to operate independently, with **Sandoz focusing on generics and biosimilars**, while Novartis concentrates on advanced therapies such as gene and cell treatments. This restructuring is expected to unlock shareholder value and improve operational efficiency.

Novartis plans to increase investments in **cutting-edge research areas**, including oncology, cardiovascular diseases, and immunology. By streamlining its portfolio, the company aims to strengthen its position in high-growth therapeutic segments.

The spin-off also allows for more **targeted capital allocation**, ensuring that resources are directed toward innovation-driven projects with higher returns.

This is expected to enhance long-term profitability and competitiveness.

This strategic move reflects a broader industry shift, where pharmaceutical companies are restructuring to focus on **core competencies and high-value innovation pipelines**.

AstraZeneca Invests in India R&D Hub to Boost Global Innovation

AstraZeneca has announced the launch of a **state-of-the-art R&D center in India**, aimed at strengthening its global research capabilities and tapping into the country's growing scientific talent pool.

The new facility will focus on **early-stage drug discovery, clinical research, and data science**, supporting AstraZeneca's global pipeline across multiple therapeutic areas. India's strong ecosystem of scientists and engineers makes it an ideal location for innovation-driven investments.

The company plans to integrate **digital health technologies and AI tools** within the center, enabling faster and more efficient research processes. This aligns with AstraZeneca's strategy of leveraging technology to enhance productivity and accelerate innovation.

The expansion is also expected to create **high-skilled employment opportunities**, contributing to the growth of India's pharmaceutical and biotechnology sectors. It further strengthens the country's position as a global hub for pharma R&D.

This investment reflects AstraZeneca's long-term commitment to **emerging markets** and highlights the increasing importance of India in the global pharmaceutical landscape.

GSK Signs Global Vaccine Partnership to Expand Market Reach

GSK has entered into a **strategic global partnership** with a biotech firm to co-develop and commercialize next-generation vaccines. The collaboration aims to expand GSK's already strong vaccine portfolio and address emerging infectious diseases.

The agreement includes **joint research, development, and commercialization rights**, enabling both companies to leverage their strengths in vaccine technology and global distribution. This partnership is expected to accelerate the development of innovative vaccine platforms. GSK will utilize its extensive manufacturing and supply chain network to ensure **rapid global distribution**, particularly in low- and middle-income countries. This aligns with its commitment to improving global health access.

The collaboration also focuses on **mRNA and protein-based vaccine technologies**, reflecting the growing importance of advanced platforms in modern vaccine development.

This move highlights the increasing role of **strategic alliances in the pharmaceutical industry**, where collaboration is key to addressing complex global health challenges and driving business growth.

Wiggens **Laboratory Shakers** – One Solution for Every Mixing Need

Wiggens laboratory shakers are designed to deliver precision, reliability, and versatility for today's demanding research and industrial laboratories. Combining rocking, waving, orbital, and microplate shaking technologies, Wiggens offers a complete mixing solution that adapts effortlessly to a wide range of applications—from gentle sample agitation to high-speed microplate processing.

Key Specifications & Features

1. Supports multiple shaking modes including rocking, waving, orbital, and microplate shaking for versatile laboratory applications
2. Wide speed ranges from gentle mixing (10 rpm) to high-speed shaking (up to 1,500 rpm) with precise digital control
3. Adjustable motion parameters such as tilt angle and orbital diameter for optimal sample handling
4. High load capacity platform suitable for flasks, bottles, gel trays, and microplates (96/384 well)
5. Quiet, vibration-free operation with long-life, maintenance-free motor
6. Compact benchtop design with non-slip platform and interchangeable accessories

Built with German-engineering excellence, Wiggens shakers provide accurate speed control across a wide operating range, ensuring consistent and reproducible results.

The stable, vibration-free operation protects sensitive samples while supporting higher loads, making these shakers ideal for continuous daily use in busy laboratory environments.

The versatile platform design accommodates flasks, bottles, gel trays, and standard 96/384-well microplates, reducing the need for multiple instruments. With intuitive digital controls, timer and continuous modes, and maintenance-free motors, Wiggens shakers help laboratories improve efficiency, save bench space, and reduce operational downtime.

Compact yet powerful, Wiggens shakers are trusted worldwide in pharmaceutical, biotechnology, diagnostics, quality control, and academic research laboratories. Whether for cell culture, ELISA, PCR preparation, gel staining, hybridization, or microbiological studies, Wiggens delivers dependable performance you can rely on.

One platform. Multiple applications. Proven reliability.

Choose Wiggens Laboratory Shakers to experience precision mixing, long-term durability, and a single platform that meets all your laboratory shaking requirements.

Scan here to know more:

analytica Hanoi 2026

APRIL 22 - 24, 2026 I International Exhibition Center (I.C.E) I Hanoi, Vietnam

The Dedicated Showcase for Science and Laboratory Solutions in Northern Vietnam



VISITOR REGISTRATION NOW OPEN

3,000+	100+	30+	30+
Trade Visitors	Exhibitors & Brands	Participating Speakers	Presentations

Step into northern Vietnam's fast-growing market and connect with over 3,000 laboratory professionals, decision-makers, and buyers at analytica Vietnam's special edition taking place from 22-24 April 2026 in Hanoi.

ON-FLOOR CONTENT

Join us at the high-level scientific conference and the Elite Forum, featuring experts speakers who will share key updates, emerging trends and practical insights across the laboratory, analysis, biotechnology and diagnostics sectors.

UNLIMITED EXPLORATION AWAITS

Countless of activities, potential connections and onsite promotions are waiting for you. Get your visit pass today!

www.analyticavietnam.com

analyticavietnam@mmiasia.com.sg

Dual stage **degasser vacuum pump**

Biotech Fluidics has introduced a **durable dual stage moulded vacuum pump** designed to improve your fluidic degassing experience**.**

The new **StabiliX™** range of vacuum pumps is engineered to provide stress-free operation with consistency, reliability, and long life for degassing applications where dissolved gases and bubbles are problematic.

Available in **analytical and prep scale versions** - StabiliX™ is quiet, durable, and retrofittable to Biotech Fluidics complete range of **DEGASi®** inline degassers incorporating vacuum pumps.

Benefitting from a completely inert wetted path - StabiliX™ vacuum pumps can be productively used to help remove gas bubbles from almost any fluid. The analytical scale version is designed for standard degassing chambers and fluids. The prep scale versions are designed to handle high vapor loads from high flow rate chambers or fluids with low vapor pressure that will cause increased solvent pervaporation through the membrane.

Improve your fluidic degassing experience with a new StabiliX™ dual stage vacuum pump (courtesy: Biotech Fluidics)

This next generation vacuum pump is available in bottom and side-mounted versions. For further information on the new StabiliX™ range of dual stage vacuum pumps please visit https://biotechfluidics.com/next-generation-vacuum-pump-for-reliable-inline-degassers/ or contact Biotech Fluidics on + 46 300 56 91 80 / + 1-612-703-5718 / info@biotechfluidics.com.

Biotech Fluidics is a leading supplier of fluidic system solutions, liquid transfer components, degassing systems, and innovative laboratory technology to instrument developers, manufacturers, and distributors all around the world. The company's mission is to empower its customers by designing and assembling unique products, being a dependable partner, offering first-class service, in-depth knowledge, and offering advanced technical support for all the items it provides.

Hamilton Storage Transitions All Automated Systems to Green Refrigerants

Story Source/Credit: Hamilton

Hamilton Storage has completed a transition to green refrigerants across its automated storage portfolio. The Franklin, Mass.-based company announced that all automated storage systems now use natural refrigerants including propane (R-290), ethane (R-170), and carbon dioxide (R-744). These refrigerants have zero ozone depletion potential and negligible global warming potential compared to traditional hydrofluorocarbon refrigerants.

The transition addresses mounting pressure on laboratories to reduce energy consumption and emissions while preparing for tightening global refrigerant regulations, including mandates under the US AIM Act and the European Union's revised F-Gas Regulation.

"Our customers are under increasing pressure—from regulators, investors, and their own organizations—to reduce emissions and energy use," says Matt Hamilton, CEO of Hamilton Storage, in a release. "By transitioning our full automated storage portfolio to green refrigerants, we're enabling laboratories and biobanks to choose technology that supports scientific discovery and environmental responsibility at the same time."

Proven Energy Savings

Hamilton's automated BiOS system demonstrates the impact of combining automation with green refrigeration. Current BiOS installations worldwide have replaced an estimated 3,000 manual ultra-low temperature freezers, enabling biorepositories to use up to 75% less power compared with traditional manual freezer environments.

The company's entire Verso line now delivers up to 20% energy savings with natural refrigerants and offers CO2 emissions equivalent savings of thousands of times less compared to systems operating with traditional coolants, according to a release from the company. Users also benefit from quieter operation, improved temperature stability, and simplified maintenance, the company notes.

"We have invested in the most advanced technology, and this full switch to green coolants across our product line is a landmark achievement in the history of automated storage systems," says Dieter Neuschütz, vice president of Hamilton Storage in Switzerland, in a release.

Addressing Laboratory Energy Consumption

Laboratories can consume up to 10 times more energy per square foot than standard office buildings, driven largely by specialized equipment and stringent temperature control requirements. Cold storage and ultra-low temperature systems are central to this challenge.

Hamilton has launched a new awareness initiative, Choose Green. Choose Hamilton., to highlight how customers can make environmentally responsible technology choices.

"With Choose Green. Choose Hamilton., we are setting a new standard in sustainable automated cold storage," says John Genereux, vice president and general manager of Hamilton Storage in USA, in a release. "We are committed to designing technologies that protect samples and the world they come from."

Next-Generation Sequencing Library Prep System for Lower-Throughput Labs Launches

Story Source/Credit: n6

The system brings real-time, per-well amplification control to labs running targeted panels, rare variant studies, and low-input clinical samples.

n6 has launched the icon16, a 16-well next-generation sequencing (NGS) library preparation instrument designed for clinical and research labs that process lower sample volumes but require the same data quality standards as high-throughput operations. The icon16 is built on AutoNorm, the adaptive amplification technology that n6 introduced in 2024 with the icon96, a 96-well instrument that gained adoption at genomics cores and research institutions in more than 22 countries, including the Broad Institute and the University of California San Francisco, according to the company. Rather than running every sample through a fixed number of polymerase chain reaction (PCR) cycles, AutoNorm monitors fluorescence in real time at the individual well level and stops amplification the moment each sample reaches a user-defined threshold—independently of the other wells on the plate.

The approach eliminates overcycling artifacts, sample dropout, and the manual quantification and cleanup steps that are typically required before pooling, according to n6. Libraries are normalized by biology rather than by protocol, the company says.

"PCR is the starting point for every NGS library, and if that starting point is compromised, everything downstream is compromised," says Pranav Patel, PhD, MBA, co-founder and chief executive officer of n6, in a release. "The icon16 exists because the icon standard shouldn't be limited to high-throughput labs. Whether you're running 16 samples or 96, every researcher deserves data they can trust."

Designed for Low-Input and Specialized Applications

The icon16 is aimed at labs performing targeted panels, rare variant studies, low-input clinical samples, and specialized sequencing applications where 96-well capacity exceeds routine needs, according to n6. In low-input workflows—where a failed library can mean an unrecoverable sample—the consequences of suboptimal amplification are particularly acute.

> The instrument is reagent-agnostic and compatible with major library preparation kits, requiring no changes to existing NGS workflows, according to the company.

Researchers already using AutoNorm technology in higher-throughput settings have noted its impact on established workflows. "There are not many technologies that actually from the get-go can have a significant impact on established workflows," says James Docker, NGS lead and multi-omics scientist at the University of Oxford Centre for Human Genetics, in a release. "But with [AutoNorm] technology we're able to really change the way you approach PCR in library prep in general."

Availability and Upcoming Conference Presence

The icon16 is available for purchase as of March 30, 2026. The launch coincides with the Association of Biomolecular Resource Facilities 2026 annual meeting, taking place March 28–31.

Technotrans Introduces Silent **Cooling Technology** for Laboratory Equipment

Story Source/Credit: Technotrans

Technotrans will showcase new thermal management solutions designed for laboratory and analytical technology applications at Analytica 2026 in Munich, including silent Peltier cooling systems and an expanded chiller series using natural refrigerants.

The company is introducing compact Peltier cooling systems that operate without refrigerant circuits or compressors, eliminating vibrations and noise emissions during operation. These systems target sensitive measurement environments including microscopy, spectroscopy, and high-performance liquid chromatography applications.

"In analytics and laboratory technology, precise temperatures are essential for reliable results," says Denis Roessel, business development manager at technotrans systems GmbH, in a release.

"With our solutions, we provide users and OEM manufacturers with planning reliability: depending on the application, we combine highly precise temperature stability with future-proof Peltier technology or natural refrigerants."

Peltier Technology Enables Fast Response Times

The new Peltier product range includes compact stand-alone solutions and integrable modules requiring minimal installation space. The technology enables fast response times and direct adjustment of cooling capacity, according to the company.

"The Peltier principle enables an extremely fast response time and direct adjustment of the cooling capacity. We support our customers from the initial problem definition through to the integration of the modules directly into the analytical device," says Roessel in a release.

The portfolio also includes miniature compressor solutions that provide high cooling capacity in small footprints.

PRO300 Series Uses Natural Refrigerant

Technotrans has expanded its PRO300 chiller series to use R290 (propane), a natural refrigerant with a Global Warming Potential of 0.02. The systems meet future regulatory requirements in Europe and the US while offering temperature stability of less than ±0.1 Kelvin for demanding laser and analytical applications.

The series features modern communication interfaces and flexible integration capabilities for existing laboratory infrastructures, according to the company.

Healthcare Focus Supports Growth Strategy

The laboratory cooling solutions support technotrans' "Ready for Growth 2030" corporate strategy, which identifies healthcare and analytics as a focus market. The company aims to leverage its engineering expertise to develop solutions meeting precision and purity standards required by medical progress and bioanalytics applications.

SPT Labtech Partners to Develop Automated Genomics Platform for Smaller Labs

Story Source/Credit:SPT LabTech



SPT Labtech announced a collaboration with Illumina to develop an automated sample preparation platform designed to streamline genomics workflows in decentralized healthcare environments.

The partnership will focus on creating a platform that supports laboratories using Illumina's MiSeq i100 benchtop sequencing system, enabling smaller labs to access the same level of automation and precision as large core facilities. The collaboration aims to help labs support improved patient care in oncology by enabling broader access to high-quality genomic characterization of disease.

"This next phase of collaboration with Illumina reflects our shared focus on enabling efficient and accessible genomics workflows, further expanding SPT Labtech's presence in the clinical genomics market," says Rob Walton, chief executive officer at SPT Labtech, in a release. "With the rapid global adoption of Illumina's MiSeq i100 platform and the recent shipment of its 1,000th system, there is a growing demand from laboratories seeking to perform their sequencing operations in-house, thereby maximizing control and reducing turnaround times."

Building on Existing Partnership

The collaboration builds on the success of an existing partnership between the companies, including development of automated library preparation methods on SPT Labtech's firefly platform. The new platform will provide standardized, automated workflows designed to enable laboratories to achieve rapid, high-quality insights closer to where critical decisions are being made.

The solution is designed to make high-quality next-generation sequencing more accessible to labs around the world by bringing advanced automation to laboratories of all sizes and settings, according to the companies. This approach aims to accelerate the delivery of actionable insights from sample to result.

sptlabtech

"Labs around the world rely on Illumina for high-quality, reliable insights and end-to-end workflows that make it easier for them to unlock crucial genomic insights faster," says Todd Christian, senior vice president of services, arrays, and genomic access at Illumina, in a release. "This collaboration builds on that history and doubles down on our commitment to expand access to next-generation sequencing for labs of all sizes, ultimately enabling researchers and clinicians to drive breakthroughs that matter for the patients they serve."

The novel platform will enable decentralized labs to access automation capabilities that were previously available primarily to large core facilities, potentially reducing turnaround times and increasing control over sequencing operations for smaller laboratory settings.

Cenevo Launches Two AI Agents to Automate Lab Workflows

Story Source/Credit: Cenevo



Cenevo has introduced two new AI agents designed to automate laboratory workflows and reduce manual overhead while maintaining compliance standards.

The London-based company, which specializes in lab management systems and AI technology for life sciences, launched the AI Protocol Conversion agent and AI Automation agent as part of its strategy to help scientists operate more efficiently.

Cenevo
mosaic · labguru

"Our AI initiatives are designed to eliminate manual work at the two biggest friction points in laboratory operations: getting knowledge into the system and turning that knowledge into action," says Keith Hale, chief executive officer at Cenevo, in a release. "We want to give scientists the power to use AI to autonomously solve complex, multi-step workflows, allowing them to focus on the more impactful aspects of their activities."

Protocol Conversion and Workflow Automation

The AI Protocol Conversion agent automatically converts legacy paper-based documents and protocols into structured, reusable, and compliant digital protocols. The system maps content within Labguru's native elements, including steps and forms, while preserving existing protocol structures and eliminating manual copy-paste and reformatting tasks.

The AI Automation agent allows scientists to describe automation requirements without programming expertise. The agent reduces implementation time and costs by 30% to 50% by generating underlying workflow logic and code automatically, with human-in-the-loop approvals and full audit trails.

The automation agent uses Labguru data and integrations with external systems to create event-driven workflows triggered by experiment status, quality control thresholds, or sample changes. The workflows remain fully visible, editable, and compliant with FDA 21 CFR Part 11 and GxP requirements.

Creating Continuous Workflow Loop

Together, the two agents create a continuous loop from structured data to automated action. The Protocol Conversion Agent imports knowledge into the system, while the Automation Agent converts that structure into proactive workflows.

"With the addition of these new AI agents, and many more to come, scientists' time will be freed to delve deeper into their research," says Jonathan Gross, chief product officer at Cenevo, in a release. "Generating scientific results requires physical analyses by multiple instruments. That makes AI adoption more challenging than in data-only industries. That's why we're building on our existing foundation of integration and connectivity to help labs to accelerate their adoption of gen AI and agentic AI."

Cenevo demonstrated the agentic AI technology at the Society for Laboratory Automation and Screening conference in Boston from Feb 9-11.

nRichDX and **Hamilton** Expand Automated Liquid Biopsy Sample Prep Capabilities

nRichDX and Hamilton announced progress on their strategic collaboration to deliver automated liquid biopsy sample preparation solutions, combining the nRichDX Revolution Plus Sample Prep System with the Hamilton Microlab STAR liquid handling platform. The integrated solution enables automated, end-to-end workflows for isolating circulating cell-free DNA (cfDNA), circulating cell-free RNA (cfRNA), circulating cell-free total nucleic acid (cfTNA), and circulating tumor cells (CTCs) from plasma, urine, and other biofluids. The system accommodates sample input volumes ranging from 1 mL to 100 mL in a single extraction.

"nRichDX is setting a new standard for liquid biopsy sample preparation performance and workflow efficiency," says William Curtis, CEO of nRichDX, in a release. "Together with Hamilton, we're enabling laboratories to achieve the highest analyte yields while benefiting from flexible, scalable automation."

Scalable Automation for Rare-Analyte Extraction

The collaboration, unveiled at the Association for Molecular Pathology Annual Meeting & Expo 2025, provides laboratories with walk-away automation for sensitive rare-analyte extraction.

The solution aims to address yield limitations and workflow variability in liquid biopsy sample preparation.

The integrated platform delivers higher analyte yields, improved workflow efficiency and reproducibility, and flexibility in sample processing volumes. By eliminating yield-reducing steps such as pre-concentration, pooling, and re-elution, the system maximizes analyte recovery from blood, plasma, urine, and other biofluids.

"Our collaboration with nRichDX reflects Hamilton's commitment to advancing precision medicine through robust, validated automation," says Michael Mouradian, vice president of scientific strategy & market development at Hamilton, in a release. "By integrating the Revolution Plus System with the Hamilton Microlab STAR platform, we are enabling laboratories to achieve reproducible, high-performance liquid biopsy workflows that flexibly scale with both research and clinical demands."

Clinical and Research Applications

At AMP 2025, the collaboration featured scientific presentations and multiple posters highlighting automated liquid biopsy workflows. The solution attracted interest from molecular diagnostics, translational research, and clinical laboratory professionals seeking to overcome challenges in rare-analyte extraction.

The companies report that joint development, customer pilots, and expanded commercial activity are currently underway based on engagement from the conference.

nRichDX's Revolution Sample Prep System is designed as an IVD-labeled platform that processes volumes from 1 mL to 100 mL in a single extraction using the company's nRicher Cartridges. Hamilton's Microlab STAR platform provides precision liquid handling and laboratory automation capabilities.

Both companies are continuing to develop the integrated solution for research and clinical laboratory applications in liquid biopsy sample preparation.

Photo caption: The nRichDX Revolution Sample Prep Plus Processor for liquid biopsy (left) shown with the Hamilton Microlab STAR liquid handling platform (right).
Photo credit: nRichDX and Hamilton

Biotage Launches PrepXpert-8 for Fully Automated Sample Preparation

Biotage has unveiled the **PrepXpert-8**, a cutting-edge automated sample preparation system designed to address the increasing need for efficiency and reproducibility in analytical laboratories. The system is particularly targeted at environmental, pharmaceutical, and food safety testing labs, where high-throughput sample processing is essential for timely results.

The PrepXpert-8 features an **8-channel parallel processing capability**, enabling laboratories to handle multiple samples simultaneously without compromising accuracy. This dramatically reduces processing time and enhances throughput, making it ideal for workflows such as PFAS, pesticide residue, and semi-volatile organic compound analysis. Its automation eliminates repetitive manual steps, allowing scientists to focus on data interpretation rather than routine tasks.

One of the system's most significant advantages is its ability to **minimize cross-contamination and human error**, which are critical concerns in regulated environments. By standardizing sample preparation procedures, the PrepXpert-8 ensures consistent and reproducible results, which are essential for compliance with global regulatory standards.

The system also integrates seamlessly with **Laboratory Information Management Systems (LIMS)**, enabling real-time data tracking and workflow optimization. This connectivity supports digital transformation initiatives in laboratories, allowing for better decision-making and streamlined operations.

As laboratories continue to adopt automation to meet increasing testing demands, the PrepXpert-8 represents a major step forward in achieving efficiency, accuracy, and scalability in modern analytical workflows.

BRANDTECH Scientific Introduces Transferpette® Pro for Precision Liquid Handling

BRANDTECH Scientific has introduced the **Transferpette® Pro Micropipette**, a next-generation liquid handling solution engineered to deliver unmatched accuracy and user comfort in laboratory environments. This latest innovation addresses the growing demand for precision in applications ranging from molecular biology to clinical diagnostics.

The standout feature of the Transferpette® Pro is its **dual calibration capability**, which allows users to adjust pipetting parameters based on different liquid properties. This ensures consistent performance even when handling challenging substances such as viscous, volatile, or temperature-sensitive liquids. Such flexibility is particularly valuable in advanced research settings where precision is critical. In addition to its technical capabilities, the micropipette is designed with **enhanced ergonomics**, reducing hand strain during repetitive tasks. This is a crucial consideration for laboratory professionals who perform pipetting operations for extended periods. The lightweight construction and intuitive controls further improve user experience and operational efficiency.

The device also incorporates **robust durability and easy maintenance features**, ensuring long-term reliability in demanding laboratory conditions. Its modular design allows for quick servicing, minimizing downtime and maintaining productivity.

As laboratories strive for higher accuracy and efficiency, the Transferpette® Pro stands out as a reliable tool that combines precision, comfort, and innovation, supporting the evolving needs of modern scientific research.

AutoGen Unveils SAFE® Tube Laser Marker for Rapid Sample Traceability

AutoGen has launched the **SAFE® Tube Laser Marker**, a breakthrough system designed to revolutionize sample identification and traceability in high-throughput laboratories. As sample volumes continue to grow, accurate labeling has become a critical factor in maintaining data integrity and operational efficiency.

The SAFE® system offers **high-speed laser marking capabilities**, enabling laboratories to label hundreds of tubes per hour with precision and consistency.

Unlike traditional labeling methods, laser marking produces permanent, smudge-proof codes that remain legible even under extreme storage conditions, such as freezing or chemical exposure.

One of the key advantages of this system is its ability to **eliminate labeling errors**, which can lead to costly mistakes in research and diagnostics. By automating the labeling process, the SAFE® Tube Laser Marker ensures accuracy and reliability, significantly reducing the risk of sample misidentification.

The system is also designed for seamless integration with **laboratory data management platforms**, allowing for real-time tracking and improved workflow coordination. This connectivity enhances compliance with regulatory standards and supports the growing emphasis on digital laboratory ecosystems.

With increasing pressure on laboratories to process large volumes of samples efficiently, AutoGen's SAFE® Tube Laser Marker provides a powerful solution for improving traceability, accuracy, and productivity.

CE FDA NSIC CERTIFIED CO. ISO 13485 Quality Management System ISO 9001:2008

YORCO®

FACTUAL LEGACY SINCE 1964

YORCO Grossing Station

EVOLVE YOUR LAB WITH ADVANCE TECHNOLOGY



- High performance airflow
- Negative pressure air curtain/air flap
- Unique top fume catchment slots
- Crucially designed
- Ease of Use
- Integral Ventilation
- UV Disinfection
- Simplified controls
- Under Table tub wash

Model: YSI-222 Ex

YORCO®

YORK
SCIENTIFIC INDUSTRIES
PRIVATE LIMITED

Laboratory Equipment & Instruments

+91-1204741800

www.yorco.co.in

sales@yorco.co.in

PUBLISHED ON: 25th March 2026 RNI NUMBER: UPENG/2017/73675

Automation, Safety and Compliance
for Maximum Return on Investment

XPR Automatic Balances offer a standalone solution for highly accurate, reproducible and safe automated weighing of powders and liquids.

Smallest Minimum Weight
Thanks to the outstanding accuracy of automated weighing, the balance minimum weight can be reduced by up to 30%. This means you can make considerable savings by using less of your expensive and rare samples.

Flexibility of Use
With just one click, the dosing head moves up and you can use your balance for all your manual weighing applications in the usual way.

Maximum User Protection
Automated weighing protects you from toxic and chemically aggressive substances. Hazardous samples are dispensed directly into the target container, avoiding manual sample handling and eliminating spills.

Perfect Concentrations
Prepare highly accurate concentrations as low as 0.1 mg/g in just one step. The balance calculates the precise amount of solvent required based on the amount of substance dosed to produce the target concentration.

Write to us
at sales.sales@mt.com or
Call Toll Free at 1800 22 8884 / 1800 10 28460
or visit us at www.mt.com

METTLER TOLEDO

www.mt.com/xpr-automatic